Pearce Nicholas M, Skyner Rachael, Krojer Tobias
Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Amsterdam, Netherlands.
OMass Therapeutics, The Oxford Science Park, Oxford, United Kingdom.
Front Mol Biosci. 2022 Apr 11;9:861491. doi: 10.3389/fmolb.2022.861491. eCollection 2022.
The throughput of macromolecular X-ray crystallography experiments has surged over the last decade. This remarkable gain in efficiency has been facilitated by increases in the availability of high-intensity X-ray beams, (ultra)fast detectors and high degrees of automation. These developments have in turn spurred the development of several dedicated centers for crystal-based fragment screening which enable the preparation and collection of hundreds of single-crystal diffraction datasets per day. Crystal structures of target proteins in complex with small-molecule ligands are of immense importance for structure-based drug design (SBDD) and their rapid turnover is a prerequisite for accelerated development cycles. While the experimental part of the process is well defined and has by now been established at several synchrotron sites, it is noticeable that software and algorithmic aspects have received far less attention, as well as the implications of new methodologies on established paradigms for structure determination, analysis, and visualization. We will review three key areas of development of large-scale protein-ligand studies. First, we will look into new software developments for batch data processing, followed by a discussion of the methodological changes in the analysis, modeling, refinement and deposition of structures for SBDD, and the changes in mindset that these new methods require, both on the side of depositors and users of macromolecular models. Finally, we will highlight key new developments for the presentation and analysis of the collections of structures that these experiments produce, and provide an outlook for future developments.
在过去十年中,大分子X射线晶体学实验的通量大幅提升。高强度X射线束、(超)快速探测器的可用性增加以及高度自动化推动了这种效率的显著提高。这些进展反过来又刺激了几个专门的基于晶体的片段筛选中心的发展,这些中心每天能够制备和收集数百个单晶衍射数据集。与小分子配体结合的靶蛋白的晶体结构对于基于结构的药物设计(SBDD)至关重要,其快速更新是加速开发周期的先决条件。虽然该过程的实验部分已经明确界定,并且目前已经在多个同步加速器站点建立,但值得注意的是,软件和算法方面受到的关注要少得多,新方法对既定的结构确定、分析和可视化范式的影响也是如此。我们将回顾大规模蛋白质-配体研究的三个关键发展领域。首先,我们将研究用于批量数据处理的新软件开发,随后讨论SBDD结构分析、建模、精修和沉积方面的方法变化,以及这些新方法在大分子模型的 depositors 和用户方面所需的思维方式变化。最后,我们将突出这些实验产生的结构集合的展示和分析方面的关键新进展,并对未来发展进行展望。